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ABSTRACT
EFFECTS OF 1α,25-DIHYDROXYVITAMIN D3 (CALCITRIOL) ON CULTURED
GLIOBLASTOMA MULTIFORME CELLS
By
Justine M. Pinskey
Glioblastoma multiforme (GBM) is an aggressive, incurable type of brain tumor.
Brain tumor stem cells (BTSCs) make up a small subset of GBM cells. BTSCs resist
standard treatments, initiate recurrence, and pose a significant challenge for GBM
treatment. This study examined gene expression and proliferation of GBM cells in vitro
to evaluate the effects of 1α,25-dihydroxyvitamin D3 (vitamin D3) treatment. Vitamin
D3 is a safe, natural inhibitor of the hedgehog signaling pathway—a mechanism essential
to BTSC function. The data in this study demonstrate that the hedgehog signaling
pathway is active in both differentiated GBM cell lines and GBM-derived BTSCs.
Vitamin D3 reduced GBM cell proliferation, especially in BTSC lines, although the dose
at which vitamin D3 was effective varied within the studies. Vitamin D3 also prevented
neurosphere formation from a single cell suspension and induced apoptosis in BTSCs,
indicating its potential as a therapeutic agent. Because of active vitamin D3’s
environmental instability, an in vivo model might provide a more complete indication of
its anti-tumor effects. Ultimately, vitamin D3 may enhance standard GBM treatments by
disabling BTSCs, but further research is needed to determine vitamin D3’s role in
modulating the growth of GBM cells.
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This thesis is dedicated to those who are suffering or have suffered from Glioblastoma
Multiforme, and to those who work hard every day to improve GBM treatments.
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INTRODUCTION

The World Health Organization classifies Glioblastoma multiforme (GBM) as a
grade IV astrocytoma, indicating this deadly cancer’s ability to grow and spread quickly.
GBM is not only the most malignant, but also the second most common primary brain
tumor in adults (CBTRUS, 2011). Additionally, brain tumors including GBM represent a
leading cause of cancer-related death in children (Dirks, 2010). Despite aggressive
multimodal treatments, including radiation and chemotherapy, patients diagnosed with
GBM have a median survival of only fifteen months (ACS, 2010). Moreover, the 1-year
survival rate for GBM patients in the United States from 1995-2007 was only 34.60%,
lower than any other type of malignant brain tumor (CBTRUS, 2011). Tremendous
research efforts have been made within the last few decades to improve GBM treatment,
but these efforts have encountered very little success, and finding new treatment targets
remains difficult. Because of its location and aggression, GBM treatment is one of the
most significant challenges faced by cancer researchers today.
Brain tumor stem cells (BTSCs) have recently emerged as a potential target for
GBM treatment. BTSCs are transformed cells that retain stem cell-like properties,
including the ability to differentiate into many cell types and the capacity for self-renewal
(Vescovi, Galli, & Reynolds, 2006). Although BTSCs represent only a fraction of the
cells in a tumor, they are thought to be largely responsible for tumor formation and
recurrence (Clark, Treisman, Ebben, & Kuo, 2007; Galli et al., 2004; Kondo, 2004).
While traditional cancer treatment methods like radiation and chemotherapy often target
the most rapidly dividing cells in a tumor, BTSCs avoid destruction because of their
1

limited replication and enhanced ability to repair DNA damage (Bao et al., 2006). BTSCs
that remain in the body after traditional cancer treatments may drive the formation of
secondary tumors, which often cause GBM death by spreading to vital areas of the brain
(Holland, 2000). Clinically, increased BTSC representation in GBM tumors negatively
correlates with overall and progression free-survival (Pallini et al., 2008). While further
research is necessary to fully understand and characterize BTSCs, developing new
therapies that effectively target these cells will have drastic implications for GBM
treatment.
To this end, a number of developmental pathways thought to be important in both
normal neural stem cell function and BTSC function are being investigated (Clark, et al.,
2007). Among them, the hedgehog signaling pathway is active in a subset of primary
GBM tumors and implicated in BTSC-related tumorigenesis (Bar et al., 2007). Hedgehog
signaling acts in normal stem and progenitor cells to regulate embryonic development.
The hedgehog ligand (Hh) binds to a cell surface receptor called Patched (Ptch), which
then relieves its inhibition of another protein Smoothened (Smo). Once Smo is free, it
initiates a cascade of molecular signals, resulting in the activation of several members
within the Gli family of proteins. Gli proteins act within the nucleus to regulate the
expression of multiple target genes involved in cell growth and proliferation, including vmyc myelocytomatosis viral related oncogene (MYCN), cyclin D2, and IGF2
(Marcotullio et al., 2004). In addition, hedgehog signaling upregulates transcription of
response genes Gli1, Gli2, Ptch1, and Hip (the gene that encodes the hedgehog
interacting protein), which have been used in the literature to asses hedgehog pathway
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activation (Aparicio et al., 2007; Clement, Sanchez, de Tribolet, Radovanovic, & Ruiz i
Altaba, 2007).
1α,25-dihydroxyvitamin D3 (vitamin D3), also known as calcitriol, has been
shown to block hedgehog signaling by binding to Smo and has independently been
associated with positive treatment outcomes for GBM patients (Bijlsma et al., 2006;
Trouillas, Honnorat, Bret, Jouvet, & Gerard, 2001). This study sought to explore the
effects of vitamin D3 on GBM cell proliferation in vitro, with the hypothesis that vitamin
D3 would block hedgehog signaling and thus inhibit GBM cell proliferation. Because
hedgehog signaling is more active within the BTSC population than in differentiated
cells, vitamin D3 treatment may be an effective way to target BTSCs specifically. A
secondary goal of the study was to compare vitamin D3’s effectiveness with that of
cyclopamine, a toxic Smo inhibitor not suitable for therapeutic use. Should vitamin D3
effectively disable GBM growth in vitro, it may make a safe and inexpensive supplement
to standard GBM treatments.
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CHAPTER 1: LITERATURE REVIEW

Introduction
Glioblastoma Multiforme is an aggressive, incurable type of brain malignancy.
Recent evidence suggests that the hedgehog signaling pathway may be implicated in
GBM tumorigenesis and important for BTSC function. Vitamin D3, a safe, natural
hedgehog pathway inhibitor, has been previously correlated with reduced tumor burden,
although its mechanism of action is incompletely understood. This chapter highlights
advances in the seemingly disparate research areas of hedgehog signaling and vitamin D3
research in the context of GBM treatment, emphasizing the overlap between these
different areas and identifying gaps in our current knowledge.
A Brief Overview of Hedgehog Signaling
Originally discovered in Drosophila melanogaster, the hedgehog signaling
pathway is present in many taxa, both vertebrate and invertebrate (Hooper & Scott,
2005). While the cellular machinery to execute hedgehog signaling has been largely
conserved between insects and mammals, the pathway’s target genes vary based on tissue
type and phyla (Hooper & Scott, 2005). In general, the main roles of hedgehog signaling
include controlling developmental patterning, regulating proliferation, and regulating
differentiation of stem and precursor cells (Yang, Xie, Fan, & Xie, 2010). The pathway is
activated when a secreted signaling protein encoded by the hedgehog gene (hh) binds to a
receptor on the cell’s surface to initiate a series of downstream effects.
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In humans and other mammals, three hedgehog genes have been characterized:
sonic hedgehog, indian hedgehog, and desert hedgehog (Shh, Ihh, and Dhh, respectively)
(Hooper & Scott, 2005). For the purposes of this review, the signaling ligands encoded
by these three genes will be simply referred to as Hh, despite potential differences in
biologic activity. Hedgehog signaling is initiated when the Hh ligand binds to Patched
(Ptch), a 12-transmembrane receptor protein found on the cell surface, causing it to be
internalized via endocytosis and undergo lysosomal degradation (Hooper & Scott, 2005).
Hh binding functions to relieve Ptch’s inhibition of a seven-transmembrane protein
Smoothened (Smo), which in turn initiates a cascade of downstream molecular signals.
Although the mechanisms by which Ptch inhibits Smo is not well understood, Ptch
contains evolutionarily conserved sterol-sensing domains that have been deemed
necessary for Smo repression (Hooper & Scott, 2005). It has been proposed that Ptch acts
as a pump, moving 3β-hydroxysteroid molecules into the extracellular space that then
bind to Smo and inhibit its function, potentially acting both intercellulary and
intracellularly (Bijlsma, et al., 2006).
When the hedgehog pathway is inactive, members of the Gli family of
transcription factors are retained in a cytoplasmic complex which includes proteins such
as Fused, Suppressor of Fused (SuFu), and structural protein KIF7 (di Magliano &
Hebrok, 2003; Hooper & Scott, 2005). When the Hh ligand binds, Ptch inhibition of Smo
is relieved, allowing Smo to regulate the activity of downstream molecules (Figure 1).
Although Smo’s mechanism of action remain unclear, it is thought that Smo acts as a
type of G-Protein coupled receptor (Ayers & Thérond, 2010), that causes the release of
Gli proteins from the cytoplasmic complex, allowing them to move into the nucleus and
5

regulate transcription of target genes (Hooper & Scott, 2005). The Gli family of proteins
includes Gli1, Gli2, and Gli3, which are expressed in different tissue types at varying
stages of development and have unique roles within the cell. Gli1 and Gli2 act as
transcriptional activators, while Gli3 primarily represses transcription (Hooper & Scott,
2005). Depending on the ratio of activation and repression by Gli1 transcription factors,
target genes can be specifically regulated. A sample of the many target genes regulated
by Gli family proteins act to increase cellular proliferation, including v-myc
myelocytomatosis viral related oncogene (MYCN), cyclin D2, and IGF2 (Marcotullio, et
al., 2004). In addition, hedgehog signaling upregulates the transcription of its own
pathway members Gli1, Gli2, Ptch1, and Hip in a positive feedback loop. Gli1 and Ptch1
in particular have been used in the literature to assess hedgehog pathway activation
(Aparicio, et al., 2007; Clement, et al., 2007).
Hh

Inactive

Active
Ptch

Smo

Gli

Hh
Ptch

Fused

Smo

Gli

Sufu

Fused
Sufu

Target
Genes
Figure 1: General hedgehog signaling mechanism. When the hedgehog ligand (Hh) is unbound, patched (Ptch)
inhibits smoothened (Smo) and the fused/Sufu complex retains Gli proteins in the cytoplasm, rendering the
pathway inactive (left). Upon Hh ligand binding, Ptch inhibition of Smo is relieved, allowing Gli proteins to move
into the nucleus and regulate target gene expression (right).
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Hedgehog Signaling in GBM and Other Cancers
The hedgehog signaling pathway has recently been implicated in human disease,
including cancer (Hooper & Scott, 2005). Aberrant hedgehog signaling has been noted in
malignancies such as leukemia, breast cancer, prostate cancer, pancreatic cancer, basal
cell carcinoma, gastrointestinal cancers, medulloblastoma, glioma, and some forms of
lung cancer (Aparicio, et al., 2007; Berman et al., 2002; Chi et al., 2006; Clement, et al.,
2007; Watkins et al., 2003; Yang, et al., 2010). The pathway can be altered at several
points to become oncogenic. Loss or inactivation of the Sufu gene, which encodes a
member of the cytoplasmic complex that retains Gli in the cytoplasmic compartment, and
overexpression of the Hh gene have been described in subsets of lung cancers, indicating
that movement of free Gli to the nucleus is associated with a malignant phenotype (Chi,
et al., 2006). Likewise, Ptch and Smo mutations have been implicated in
medulloblastoma and prostate cancer (Aparicio, et al., 2007; Ellison et al., 2011). The
natural suppression of the hedgehog signaling pathway can be disrupted at a number of
different levels to cause disease, and until the pathway is fully characterized, we will lack
a complete understanding of its aberrant effects.
Only recently has the hedgehog signaling pathway been implicated in GBM
progression. In 2007, Eli Bar and colleagues described Smo, Ptch, and Gli1 expression in
several GBM tumor cell lines as well as GBM-derived neurospheres—concentrated
populations of brain tumor stem cells isolated from tumor samples (2007). Treating GBM
cells with cyclopamine, a hedgehog pathway inhibitor that binds to the Smo protein,
decreased Gli1 expression and reduced the growth of GBM cells in culture. Cyclopamine
treatment depleted the stem cell population and prevented the formation of new
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neurospheres, indicating that hedgehog signaling is indeed an important part of BTSC
establishment and function (Bar, et al., 2007).
Furthermore, Bar’s group demonstrated that hedgehog inhibition by cyclopamine
blocked the formation of new tumors. When untreated control GBM cells were implanted
into mouse brains, aggressive tumors formed, rapidly killing the mice. Pre-treating the
GBM cells with cyclopamine, however, completely abolished tumor engraftment and
growth, leading to complete survival of the cyclopamine-treated cohort of mice (Bar, et
al., 2007). These data suggest that blocking the hedgehog signaling pathway could
potentially prevent recurrence or metastasis of GBM. These and other findings warrant a
closer look into hedgehog signaling pathway mechanisms and investigation of potential
hedgehog pathway inhibitors for GBM and other malignancies.

Inhibition of Hedgehog Signaling as a Means of Cancer Treatment
While cyclopamine is often used to experimentally inhibit the hedgehog signaling
pathway, it has many potential clinical drawbacks (Bijlsma, Peppelenbosch, & Spek,
2007). In addition to being a known teratogen, cyclopamine is known to cause
widespread toxicity, and is not safe for human use. Cyclopamine’s side effects include
severe nausea, vomiting, bradycardia, syncope, paresthesia, weakness, diaphoresis,
salivation, and hypotension ("Cyclopamine," 2002). In addition, cyclopamine is difficult
to produce in mass quantities, making it an expensive, unsafe, and unrealistic treatment
option (di Magliano & Hebrok, 2003).
Many groups are working to develop novel compounds that inhibit hedgehog
signaling with less toxicity. One such synthetic analogue is 3-Keto-N-(aminoethyl-
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aminocaproyl-dihydrocinnamoyl)cyclopamine (KAAD-cyclopamine), which is 10-20
times more potent than cyclopamine and helps modulate TNF-related apoptosis-inducing
ligand (TRAIL) in glioma cells (Siegelin, Siegelin, Habel, Rami, & Gaiser, 2009; Taipale
et al., 2000). The safety of KAAD-cyclopamine currently remains largely untested, but it
is suspected that its structural similarity to cyclopamine may cause similar unwanted
effects (Figure 2). Other classes of Smo antagonists (SANT1-SANT4) (Chen, Taipale,
Young, Maiti, & Beachy, 2002) and Sonic Hedgehog-neutralizing antibodies (Yang, et
al., 2010) have been identified, but again have not yet been tested for clinical use.
Forskolin, a Gli1 inhibitor, has been shown to reduce tumor growth in
Rhabdomyosarcoma muscle tumors with limited adverse effects in mice (Yamanaka,
Oue, Uehara, & Fukuzawa, 2011). However, Forskolin has also been shown to increase
the complexity of the blood-brain barrier, a tight network of capillaries surrounding the
brain, which suggests that it may not be well-suited for GBM treatment due to delivery
complications (Wolburg et al., 1994).

Cyclopamine

KAAD-Cyclopamine

Figure 2: Chemical structures of cyclopamine and KAAD-Cyclopamine ("Chembase," 2011).
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Developing these types of therapeutics aimed to inhibit the hedgehog signaling pathway
is time-consuming and costly, and a safe, effective hedgehog inhibitor has yet to be
identified.

Vitamin D3 as an Exogenous Hedgehog Pathway Inhibitor
1α,25-dihydroxyvitamin D3 (vitamin D3) is a safe, naturally occurring
secosteroid that directly inhibits the hedgehog signaling pathway (Bijlsma, et al., 2006).
With a mode of action very similar to that of cyclopamine, vitamin D3 binds to Smo,
preventing it from inducing the signal cascade and thus preventing the transcription of
hedgehog target genes. It has been proposed that the 3β-hydroxysteroid molecule
involved in normal Ptch-dependent repression of Smo is indeed a form of vitamin D3
(Bijlsma, et al., 2006), although this has been debated and requires further investigation
(Ayers & Thérond, 2010; Wilson, Chen, & Chuang, 2009). It has also been suggested
that treatment with exogenous vitamin D3 to enhance natural hedgehog pathway
repression might be an effective way to disable BTSC function (Bijlsma, et al., 2007;
Bijlsma, et al., 2006).
Importantly, vitamin D3 naturally circulates throughout the body and crosses the
blood-brain-barrier, making it an attractive therapeutic agent for GBM (Eyles, Burne, &
McGrath, 2011). Because vitamin D3 is involved in calcium regulation, one potential
side effect of high-dose vitamin D3 treatment might be hypercalcemia, or the
overabundancy of calcium in the blood. This side effect is relatively common in cancer
patients, affecting 10-20%, but is only rarely observed in GBM patients under standard
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treatments (Seif, Azar, Barake, & Sawaya, 2006) Once vitamin D3’s therapeutic efficacy
has been determined, possible approaches to reduce the risk of hypercalcemia can be
explored, including individual dose determination, dietary restriction, and treatment
screening based on preexisting risk factors (Heaney, 2008; Vieth, 2007). Additionally,
one study showed that 1-α-dihydroxyvitamin D3 does not cause adverse side effects in
mice, while its inactive counterparts 25-hydroxyvitamin D3 and vitamin D3 induced
hypercalcemia and weight loss, suggesting that vitamin D3’s side effects may be
dependent on concentration of its various forms (DeLuca, Prahl, & Plum, 2011).
Currently, temozolomide (TMZ) is the clinically accepted standard of care for
glioblastoma patients. Temozolomide acts by methylating guanine residues at the N-7 or
O-6 position, which induces DNA damage and triggers apoptosis. Temozolomide and
vitamin D represent an attractive treatment combination, since temozolomide affects the
rapidly dividing cells in a tumor, while inhibitors of hedgehog signaling affect BTSCs,
which have limited replication and increased chemotherapeutic resistance. Clement and
colleagues recently described a synergistic effect of TMZ plus an intermediate dose
(5mM) of cyclopamine, demonstrating reduced proliferation and increased apoptosis in
both glioma stem cell cultures and U87 glioblastoma cells (Clement, et al., 2007).
Interestingly, however, interactions between vitamin D and temozolomide have not been
previously described.
Vitamin D3 has long been associated with positive cancer outcomes. A recent
review points out that numerous studies correlate vitamin D3 deficiency with increased
risk for general malignancy, although the risk for specific, individual cancers is difficult
to test, and remains unclear (Anaizi, 2010). In the United States and Canada, one group
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has gone so far to suggest that raising year-round serum vitamin D levels to 40 to 60
ng/mL would prevent 58,000 new cases of breast cancer and 48,000 new cases of
colorectal cancer every year in addition to preventing three-fourths of deaths from these
diseases (Garland, Gorham, Mohr, & Garland, 2009). It is clear that vitamin D3 is a
potentially useful cancer therapeutic, despite our incomplete understanding of its cellular
mechanisms (Beer & Myrthue, 2004). Further investigation will be necessary to
determine whether vitamin D3’s inhibition of the hedgehog signaling pathway
contributes to its anti-cancer effects. Ultimately, vitamin D3 may be a useful addition to a
therapeutic regimen for GBM and other malignancies.

Conclusion
The hedgehog signaling pathway is implicated in the tumorigenesis of GBM and
other cancers, making it an attractive therapeutic target. Although synthetic antagonists of
the pathway are currently being developed, vitamin D3 and its analogues may provide a
safe, efficient, and low-cost alternative to synthetic novel compounds for hedgehog
pathway inhibition. While the potential for vitamin D3 as a GBM treatment option is
evident within the literature, its efficacy and mechanisms of action are complex, and
remain elusive. Studies designed to further elucidate vitamin D3’s effects on GBM cells
both in vitro and in vivo will shed light on its ability to act as a hedgehog pathway
inhibitor and help determine its overall potential as a therapeutic agent.
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CHAPTER 2: CULTURE AND MAINTENANCE OF GBM CELLS

Introduction
Cell culture has long been used as a model system for GBM studies. Recently,
advances in technology and approach have allowed for culture of primary neurospheres,
or free-floating populations of stem and progenitor cells, from isolated BTSCs. The
experiments in subsequent chapters of this thesis involve both established GBM cell lines
purchased from American Type Culture Collection (ATCC) and primary GBM BTSCderived neurospheres isolated from patients at the Hermelin Brain Tumor Center at Henry
Ford Hospital and Marquette General Hospital. This chapter outlines the procedures used
to isolate, culture, and maintain the GBM cell lines that were used as model systems for
experiments in later chapters.

Adherent GBM Cell Culture
Differentiated GBM cells grow as adherent cultures that have distinct
morphological features including rapid growth and a lack of contact inhibition (Figure 3).
GBM cell lines LN 229, U-87 MG, U-138 MG, and T 98 (ATCC) were used for the
described experiments, cultured under standard conditions (37 °C, 5% CO2). LN229 cells
were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
5% fetal bovine serum (FBS). U 87 MG, U 138 MG, and T 98 lines were grown in
Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% FBS.
Passage of cell lines: Cells were passed as needed, when their confluency
approached 100%. First, the cells were detached from the flask bottoms using
13

Trypsin/EDTA. Cells were then resuspended in the appropriate media and centrifuged at
500 times gravity for approximately five minutes. After removal of the supernatant, the
cell pellet was resuspended in the appropriate media and cells and a cell count was
performed using the trypan blue exclusion method. Cells were then replated at the desired
confluency in new flasks.
Cryopreservation of cell lines: Cell stocks were kept in liquid nitrogen in the
appropriate media with 10% Dimethyl Sulfoxide (DMSO).

Figure 3: Morphological differences between differentiated GBM U 87mg cells and GBMderived 2503 neurospheres. Differentiated lines (left) grow as an adherent monolayer. Tumorderived neurospheres (right) grow as free-floating spheres. Images were obtained using an
Olympus CKX41 Inverted Fluorescent Microscope at 10x magnification.

Neurosphere Isolation and Culture
While differentiated GBM cells adhere to culture flasks, BTSCs grow as freefloating neurospheres, allowing for their selective culture in specified neurosphere media.
BTSCs were isolated from both fresh and frozen GBM tissue samples obtained from
Marquette General Hospital (Marquette, MI) and Henry Ford Hospital (Detroit, MI) with
institutional review board approval. Tumor samples were cut into one millimeter cubed
pieces using a sterile scalpel and then washed twice in Dulbecco’s Modified Eagle
14

Medium: Nutrient Mixture F-12 (DMEM/F12, Gibco). Cells were dissociated overnight
on a rotating table in collagenase (two milliliters for each half gram of tissue). The
following day, tissues were mechanically homogenized, passed through a 40 µM cell
strainer, washed, and then purified over a mouse Lympholyte column (Cedarlane
Laboratories Limited, Hornby Ontario, Canada). Briefly, the cell suspension was slowly
layered over a five milliliter lympholyte column which was then centrifuged for 20
minutes at 1300 xg at room temperature. The nucleated cells formed a layer between the
aqueous media and the lympholyte, which was transferred to a separate tube and pelleted
via centrifugation (100 xg, five-ten minutes at room temperature). The pellet was washed
twice with 10 mL of DMEM/F12 and resuspended in Neurosphere Media (NM),
NM was comprised of Dulbecco’s Modified Eagle Medium: Nutrient Mixture F12 (DMEM/F12, Gibco) supplemented with 500 µL N2 supplement (Gibco), 25 mg
bovine serum albumin (Sigma), 125 µL Gentimicin (Gibco), and 250 µL
Antibiotic/Antimycotic (Gibco) per 50 mL aliquot. Semi-complete media was filtersterilized before use and stored at four degrees Celsius for no more than 10 days.
Recombinant Human Fibroblast Growth Factor-basic (PeproTech) and Recombinant
Human Epidermal Growth Factor (PeproTech) were added to sterilized media at 100
µg/mL to make complete media (NMGF), which was freshly prepared before each use.
Neurospheres were cultured under standard conditions (37 °C, 5% CO2) in flasks
designed specifically for non-adherent cell cultures (NUNC).
Of note, neurosphere cultures from numerous different tumor samples were
attempted, but only a few readily generated robust spheres containing BTSCs that were
able to regenerate new spheres upon dissociation. Samples that formed neurospheres of
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100 µm or larger and survived through seven passages were used for further studies,
including samples 190430 and 259274. Additionally, subsequent experiments were
performed on neurosphere cell line 2503, which was a generous gift from the Hermelin
Brain Tumor Center at Henry Ford Hospital.
Media changes were performed by tilting the NUNC flasks onto their short edges
and allowing the neurospheres to settle for five minutes or longer. The top 25-33% of
media was removed and replaced with fresh NM. Growth factors were added to each
flask individually (usually two microliters per flask, depending on total volume).
Passage of neurospheres: To pass neurospheres, cells were transferred to fifteen
milliliter conical tubes and allowed to settle for five to ten minutes. Supernatant media
was removed, and the spheres were resuspended in 10 mL of sterile, calcium and
magnesium free phosphate buffered saline (PBS, Lonza). After fifteen minutes, the
solution was pipetted extensively (100 times or more) first with a fine Pasteur pipette and
then with a 0.2-10 µL clear pipette tip secured over a 2-200 µL yellow tip secured over a
100-1000 µL blue tip. The series of escalating tip sizes provided a narrow opening to
pass the neurospheres through while still allowing for a large volume (one milliliter).
Dissociated neurospheres were centrifuged at 800 G for five-ten minutes at room
temperature, resuspended in NMGF, and transferred to new flasks.
Cryopreservation: Stocks of dissociated neurospheres were kept in liquid
nitrogen in DMEM/F12 supplemented with 10% Dimethyl Sulfoxide (DMSO).
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CHAPTER 3: ANALYZING HEDGEHOG EXPRESSION IN CULTURED GBM
CELLS

Introduction
Hedgehog signaling has been shown to play an important role in glioblastoma
stem cell function. Gli1 is a transcription factor that acts as the final messenger in the
hedgehog signaling cascade, and is often used as a marker for pathway activity. The
immunocytochemistry experiments in this chapter were designed to confirm the presence
of Gli1 in LN 229, U 87 MG, U 138 MG, and T 98 cell lines (ATCC) as well as
glioblastoma-derived neurospheres (BTSCs). In addition, changes in pathway target gene
expression (Gli1 and MYCN) during hedgehog pathway inhibition were observed using
the quantitative reverse transcription polymerase chain reaction (qPCR) method. The data
indicate that Gli1 is expressed in both differentiated glioblastoma lines and glioblastomaderived BTSC lines, and that vitamin D3 treatment affects hedgehog target gene
expression. This preliminary evidence suggests that Vitamin D3 may be useful as a
therapeutic hedgehog pathway inhibitor in GBM patients.
Methods and Materials
Immunocytochemistry
Immunocytochemical staining for Gli1 was performed to assess the activity of the
hedgehog signaling pathway in LN 229, U 87 MG, U 138 MG, T 98, and GBM-derived
neurosphere cell lines. Adherent cell lines (LN 229, U 87 MG, U 138 MG, T 98) were
fixed and stained as previously described (Goldstein & Watkins, 2008). Cells were plated
at 100,000 cells per well onto ethanol-sterilized coverslips at the bottom of six-well
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plates. After 24 hours (or at approximately 70% confluency), coverslips were fixed using
fresh 4% paraformaldehyde (PFA) solution with 1% Triton (Fisher Scientific) made in
Phosphate Buffered Saline (PBS). Cells were then stained with primary polyclonal goatanti Gli1 antibody (Santa Cruz Biotechnology) diluted to five micrograms per milliliter
for one hour followed by secondary donkey anti-goat antibody conjugated to fluorescein
isothiocyanate (FITC) diluted to 2.5 micrograms per milliliter for one hour. Secondary
staining and imaging were performed in the dark. Coverslips were mounted on slides
using Vectashield Mounting Medium containing 4’,6-diamidino-2-pheynlyindole (DAPI)
for nuclear staining (Vector), and results were visualized using an Olympus BX51
Fluorescent Microscope and an Olympus FV1000 Laser Scanning Confocal Microscope.
A similar procedure was used to image GBM-derived neurospheres, but due to
their free-floating nature, they were fixed, cryosectioned, and attached to slides before
antibody treatment, as previously described (Jacqueline, Kasia, Laura, Laurie, & Shelley,
2006). Briefly, neurospheres were transferred to a 50 mL tube, allowed to settle for 30
minutes, and resuspended in two milliliters of fresh 4% PFA solution with 1% Triton
made in PBS. After settling on ice for 30 minutes, the PFA/Triton solution was removed,
and neurospheres were rinsed at least three times with fresh PBS, allowing 30 minutes of
settling time between each rinse. The neurospheres were then refrigerated overnight in
five milliliters of 30% sucrose dissolved in 0.1 M PBS. The next day, the portion of the
liquid containing the settled neurospheres was transferred to a mold between layers of
embedding medium for frozen tissue specimens (Sakura Tissue-Tek O.C.T. compound,
cat. No. 4583). The mold was then transferred to a cryostat chuck containing a layer of
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O.C.T. and cryosectioned into 40 µM slices onto Poly-L-Lysine coated glass microscope
slides. Antibody staining then proceeded as described above.
Polymerase Chain Reaction
Vitamin D3 and cyclopamine are hedgehog signaling inhibitors which bind and
inactivate the cell surface protein smoothened (Smo). To assess hedgehog signaling
inhibition in cells treated with vitamin D or cyclopamine, changes in the expression of
hedgehog target genes Gli1 and MYCN were measured using qPCR.
Before use, vitamin D3 (Sigma) was diluted to 10 µM and 1 µM aliquots in 100%
ethanol (EtOH) and stored in the dark at -20 °C. Cyclopamine was dissolved in dimethyl
sulfoxide (DMSO) and aliquoted into 12 mM stocks, also stored in the dark at -20 °C.
Neurospheres from line 2503 were dissociated into a single cell suspension, counted
using the trypan blue exclusion method, and plated in a 12-well plate at 2,143 cells per
milliliter (4,286 cells per well). Wells were then separated into five treatment groups:
untreated (UT), ethanol control (EtOH), vitamin D3 (Vit. D), dimethyl sulfoxide control
(DMSO), and cyclopamine (CYC). RNA was isolated using the Total RNA Mini Kit
(IBI) following the Total RNA Mini Kit (Tissue) Cultured Cell Protocol without the
optional steps. RNA yield was quantified using the NanoDrop2000c spectrophotometer
(Thermo Scientific). Reverse transcription was accomplished using the Reverse
Transcription System (Promega, product A3500). Complimentary DNA (cDNA) was
then diluted to 100 µL in nuclease-free water, and qPCR amplification was performed in
triplicate using a StepOne Real-Time PCR System (Applied Biosystems) with the
following primers: Gli1: 5’-TTCCTACCAGAGTCCCAAGT-3’ and 5’CCCTATGTGAAGCCCTATTT-3’; MYCN: 5’-AAAAGGCCACTGAGTATGTCC-3’
and 5’-TGTCCAGTTTTGAGAAGCGTC-3’ (Integrated DNA Technologies). Primers
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were diluted to a 10 µM concentration before use. Fold change was calculated using the
2-ΔΔCT method and plotted using Microsoft Excel.

Results and Discussion
Immunocytochemistry revealed Gli1 expression in both differentiated GBM cells
(LN 229, U 87 MG, U 138 MG, and T 98) and tumor-derived neurosphere populations
(Figures 4 and 5). Due to equipment limitations, it was impossible to accurately
determine localization or relative expression of Gli1 between samples, although
qualitatively, neurospheres generally appeared to have a more robust Gli1 expression and
a higher proportion of nuclear Gli1 than differentiated cell lines, as would be predicted
due to their stem-like state (Figure 4). Because Gli1 is a downstream member of the
pathway whose expression is regulated by pathway activity, the presence of Gli1
suggested that hedgehog signaling was active within the GBM cells. Further research
would need to be done to determine whether other pathway components were present and
intact, such as Smo or Ptch.
Because higher levels of Gli1 were found in the neurosphere populations, further
characterization of hedgehog pathway expression was focused on the 2503 BTSC line.
The polymerase chain reaction was used to quantify Gli1 and MYCN mRNA expression
in BTSCs to better analyze hedgehog pathway activity and to assess signaling changes in
the presence of pathway inhibitors cyclopamine and vitamin D3. Compared to an
untreated control (not shown) all treatment groups displayed decreased Gli1 and MYCN
expression. Gli1 expression decreased when BTSCs were treated with vitamin D3

20

A

B

Figure 4: Gli1 expression in LN 229 bulk GBM cells (A) and GBM-derived 2503 neurospheres (B). Green
staining indicates presence of an anti-Gli1 antibody conjugated to FITC. Blue represents DAPI staining for
nuclear material. Images taken at 40X magnification using an Olympus BX51 Fluorescent Microscope.

A

B

C

D

Figure 5: LN 229 (A), T 98 (B), U 87 MG (C), and U 138 MG (D) GBM cells express Gli1,
indicating hedgehog pathway expression. Green staining indicates presence of an anti-Gli1
antibody conjugated to FITC. Blue represents DAPI staining for nuclear material. Images taken
at 60X magnification using an Olympus FV1000 Laser Scanning Confocal Microscope.
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Figure 6: Vitamin D3 reduces Gli1 expression in GBM-derived 2503 neurospheres.
Quantitative reverse transcriptase polymerase chain reaction was used to determine Gli1
expression in BTSC line 2503 after treatment with vitamin D3 (Vit. D) and cyclopamine (CYC)
as compared to their vehicle controls (ethanol (EtOH) and dimethyl sulfoxide (DMSO),
respectively). Amplification was performed using a StepOne Real-Time PCR System (Applied
Biosystems).
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Figure 7: Vitamin D3 and cyclopamine reduce MYCN expression in GBM-derived
neurospheres. Quantitative reverse transcriptase polymerase chain reaction was used to
determine Gli1 expression in BTSC line 2503 after treatment with vitamin D3 (Vit. D) and
cyclopamine (CYC) as compared to their vehicle controls (ethanol (EtOH) and dimethyl
sulfoxide (DMSO), respectively). Amplification was performed using a StepOne Real-Time
PCR System (Applied Biosystems).
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compared to its vehicle control EtOH, which supports vitamin D3’s antagonistic
hedgehog effects (Figure 6). Cyclopamine treatment, on the other hand, caused an
unexpected increase in Gli1 expression compared to its vehicle DMSO (Figure 6).
Subsequent analysis revealed microscopic crystal formation in cyclopamine after storage
at -20 ºC, which could have contributed to cyclopamine’s inability to inhibit hedgehog
signaling. It would be expected, however, that Gli1 expression would be equivalent to
that of the DMSO control if the cyclopamine were inactivated due to crystallization. This
particular part of the experiment should be repeated using crystal-free cyclopamine to
confirm previous findings that cyclopamine decreases Gli1 expression due to hedgehog
signaling inhibition. Interestingly, both vitamin D3 and cyclopamine decreased the
expression of MYCN, another pathway target (Figure 7). It is unclear from the data
whether vitamin D3 regulates MYCN expression through the hedgehog pathway or
through a separate receptor-mediated mechanism. Further studies are needed to elucidate
exactly how vitamin D3 regulates MYCN expression in GBM cells.

Conclusion
Hedgehog signaling has been implicated in GBM progression. Components of the
hedgehog signaling pathway that are overexpressed in GBM cells may be important
treatment targets, especially within the BTSC population. These data confirm the
presence of the hedgehog signaling protein Gli1 in both differentiated GBM cell lines and
GBM-derived neurospheres. These data warrant further investigation into the effects of
vitamin D3 on GBM cell proliferation to further assess the therapeutic potential of
vitamin D3 as a hedgehog pathway inhibitor.
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CHAPTER 4: EFFECTS OF VITAMIN D3 ON GBM CELL PROLIFERATION

Introduction
Vitamin D3 is a natural compound that easily crosses the blood brain barrier,
inhibits the oncogenic hedgehog signaling pathway, and has long been associated with
positive outcomes for brain tumor patients. This study was designed to directly test
vitamin D3’s effects on GBM cells in vitro through proliferation and dose response
assays. Preliminary data investigating vitamin D3-mediated differentiation and apoptosis
within the BTSC population are also provided. Vitamin D3 inhibited proliferation of both
bulk GBM cells and BTSCs, prevented neurosphere formation from a single cell
suspension of BTSCs, and induced activity of caspase 3 in BTSC populations. These
results lend support to vitamin D3’s therapeutic potential and warrant further
investigation into its mechanism of action within GBM cells.

Methods and Materials
The experiments described in this chapter were performed on standard GBM cell
lines LN 229, T 98, U 87 MG, and U 138 MG in addition to GBM-derived BTSC lines
2503 and 294275. Vitamin D3’s effects on cellular proliferation, differentiation, and
apoptosis were assessed using microscopy and luminescence-based quantification
techniques.
Proliferation/Dose Response
Vitamin D3 (Sigma) was dissolved in 100% ethanol (EtOH) and diluted to 10
mM, 10 µM, and 1 µM aliquots for storage. Cyclopamine was stored in 12 mM aliquots
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after being dissolved in dimethyl sulfoxide (DMSO). Temozolomide (TMZ) was also
dissolved in DMSO, and was stored in 150 mM aliquots. All three compounds were
stored in light-tight containers at -20 °C. Prior to treatment, the appropriate media was
used to further dilute each compound to the desired concentrations, which ranged from
100 nM to 15 µM for vitamin D3 (Magrassi et al., 1998), 1 µM to 10 µM for
cyclopamine (Wang, Pan, Che, Cui, & Li, 2009), and 1 µM to 400 µM for TMZ (Beier et
al., 2008). Differentiated cell lines were plated at 5,000 cells per well in 96-well plates
and incubated under standard conditions (37 °C, 5% CO2). Treatments were applied after
cells were allowed to incubate for 24 hours. The length of treatment varied depending on
experimental protocol. BTSC populations were dissociated into single cell suspensions,
resuspended in media containing the desired treatment agents, plated into 96-well plates,
and incubated for the appropriate length of time, depending on the experiment.
The CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used to
assess proliferation. Briefly, 100 µL of activated CellTiter-Glo reagent were added to
each well, the plate was incubated at room temperature for 10 minutes, and luminescence
was detected using a Modulus Microplate Reader (Turner Biosystems). CellTiter-Glo
quantifies adenosine triphosphate (ATP), generating a luminescent signal proportional to
the number of metabolically active cells. All treatments were performed at a minimum in
triplicate and most frequently in sextuplet. Percent luminescence was determined,
indicating average luminescence values from each treatment group compared to the
average luminescence of the control. Significant differences between groups were
determined at the 0.05, 0.01, or 0.001 level using one-way ANOVA and Tukey’s Post
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Hoc analysis in PASW Statistics 18. Figures were generated in Microsoft Excel and
GraphPad Prism.
Differentiation
In order to assess vitamin D3’s effects on differentiation, BTSCs suspended in
treatment-containing media were plated at 12,500 cells per milliliter (25,000 cells per
well) onto a six-well plate with ethanol-sterilized coverslips placed at the bottom of each
well. After four days of incubation, morphological changes, particularly in sphere
formation and adherence, were observed using an Olympus CKX41 inverted fluorescent
microscope.
Apoptosis
The Caspase-Glo 3/7 Assay (Promega) was used to determine whether vitamin
D3 induced BTSC apoptosis, or programmed cell death. BTSC populations were
dissociated into single cell suspensions and resuspended in media containing no
treatment,10 µM EtOH, 10 µM vitamin D3, 10 µM DMSO, or 10 µM cyclopamine. A
blank control (media only without cells) was also included for each timepoint. Cell
suspensions were plated at 8,500 cells per well into 96-well plates and incubated for 8
and 24 hours before addition of the Caspase-Glo reagent following manufacturer
instructions. Luminescence was detected using a Modulus Microplate Reader (Turner
Biosystems) at 30, 45, 60, and 75 minutes after reagent addition. Significant differences
between groups were determined at the 0.05, 0.01, or 0.001 level using one-way ANOVA
and Tukey’s Post Hoc analysis in PASW Statistics 18. Figures were generated in
GraphPad Prism.
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Results and Discussion
Vitamin D3 inhibits proliferation of differentiated GBM cell lines with varying efficacy
Vitamin D3 had varying anti-proliferation effects on the cells, dependent on
which cell line was used and the time-point of treatment. An initial proliferation assay
using LN 229 cells indicated that Vitamin D3 at 100 nM concentration significantly
inhibited cell growth at 24, 48, and 60 hour timepoints after treatment, with p values of
0.008, 0.004, and <0.001, respectively (Figure 8). A second LN 229 proliferation assay
also appeared to show a slight vitamin D3. effect, but this effect failed to reach statistical
significance (Figure 9). This second proliferation assay also considered TMZ, which
significantly reduced the growth of the cells but was statistically indistinguishable from
its DMSO vehicle. Because of the large DMSO effect, combined effects of TMZ and
vitamin D3 could not be determined.
Multiple dose response assays were subsequently conducted to determine
effective levels of vitamin D3 on LN 229 and other cell lines. Growth was analyzed 48
hours after treatment, based on the significant results of the initial proliferation assay.
The first dose response assay using LN 229 cells clearly showed that vitamin D3 at 1000
µM (10 times the amount originally used) significantly inhibited GBM cell growth,
without significant ethanol interference (p<0.001, Figure 10). However, this result was
not duplicated in a subsequent dose response assay using LN 229 and U 87mg cell lines
(Figure 11), in which neither cell line showed significant growth inhibition for 1000 µM
or 1200 µM vitamin D3 concentrations.
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Figure 8: Vitamin D3 slightly reduces LN 229 proliferation over time. Cells were plated at 5,000 cells per
well, treated 24 hours after plating, and viable cells were detected using the CellTiter-Glo® Luminescent
Cell Viability Assay (Promega).

Figure 9: Effects of vitamin D3 and Temozolomide (TMZ) on LN 229 proliferation over time. Cells were
plated at 5,000 cells per well, treated 24 hours after plating, and viable cells were detected using the
CellTiter-Glo® Luminescent Cell Viability Assay (Promega).
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Figure 10: 1000 nM Vitamin D3 significantly inhibits LN 229 growth. Cells were plated at 5,000
cells per well, treated 24 hours after plating, and viable cells were detected after 48 hours of
incubation using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Reported values
indicate the mean of six replicates converted to percent of control (untreated) group. Significant
values indicated at p ≤ 0.001 (***).
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Figure 11: Proliferation of LN 229 and U 87mg cells is not affected by Vitamin D3 at 1000 nM or 1200
nM concentrations. Cells were plated at 5,000 cells per well, treated 24 hours after plating, and viable
cells were detected after 48 hours of incubation using the CellTiter-Glo® Luminescent Cell Viability
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(untreated) group. No significant differences were reported.
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Further dose response assays were conducted using increasing concentrations of
vitamin D3 to determine a consistently effective level. Of note, LN 229 cells showed a
significant increase in growth when treated with 5 µM vitamin D3 (p ≤ 0.001, Figure
12A). Only the highest concentration of 15 µM vitamin D3 significantly inhibited LN
229 growth (p ≤ 0.001), but this effect could not be statistically separated from the effects
of the ethanol control (p = 0.024, Figure 12). T 98 cells, on the other hand, significantly
responded to 10 and 15 µM vitamin D3 concentrations without significant ethanol effects
(p = 0.001 and 0.036, respectively, Figure 12). In the U87 cell line, significant ethanol
effects were observed at 10 µM concentration, but no significant vitamin D3 effects were
observed. The U 138 MG cell line did not appear to respond at all to treatment. (Note: U
87 MG cells and U138 MG cells were not treated at 15 µM due to a shortage of available
vitamin D3).
Because T 98 cells responded best to vitamin D3 treatment (perhaps due to
increased hedgehog expression, Figure 5), they were chosen to perform the final group of
dose responses. This time, cyclopamine and TMZ were also considered. Importantly, new
stocks of all three treatment agents were prepared, and cyclopamine and vitamin D3
dilutions were prepared in the dark. All treatments were applied at one, five, and 10 µM
concentrations. Results showed that cyclopamine significantly inhibited T 98 growth
when applied at one and 10 µM concentrations (p= 0.026 and <0.001, respectively;
Figures 13A and 13C). Vitamin D also significantly inhibited cell growth at one and 10
µM concentrations, but these effects could not statistically be distinguished from ethanol
effects (Figures 13A and 13C).
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Figure 12: Vitamin D3 has varying effects on LN 229, T 98, U 87 MG, and U 138 MG proliferation.
Cells were plated at 5,000 cells per well, treated 24 hours after plating, and viable cells were detected
after 48 hours of incubation using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega).
Values reported indicate the mean of six replicates converted to percent of control (untreated) group.
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Figure 13: T 98 cells respond to cyclopamine at 1 and 10 µM, but not 5 µM concentrations. Cells
were plated at 5,000 cells per well, treated 24 hours after plating, and viable cells were detected after
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Interestingly, no significant results were observed when treatments were applied at five
micromolar concentrations in T 98 cells (Figure 13B). Temozolomide at the chosen
concentrations had no appreciable effect on proliferation of T 98 cells (Figure 13).
Overall, proliferation assays indicated that GBM cultures were inhibited by
vitamin D3 to some extent, but results were inconsistent. Early experiments reached
significance at 100 nM concentrations (Figure 8), while later dose response assays
required much higher levels of up to 15 µM to affect proliferation within the same cell
line (Figures 10 and 12). One explanation for this phenomenon might be that 1-αdihydroxyvitamin D, the purified, active form of vitamin D3, is extremely sensitive to
degradation. Both ultraviolet light and oxygen can affect the compound’s stability, and
the effects can occur very rapidly (Lebwohl, Quijije, Gilliard, Rollin, & Watts, 2003).
Because of suspected vitamin D3 degradation, fresh stocks of all chemicals were
used for the experiments summarized in Figure 13, which were expected to again yield
growth inhibition at low concentrations. Indeed, with the exception of the five
micromolar treatment group, vitamin D3 significantly inhibited the cells’ growth.
However, a large, unexpected ethanol effect was observed. This effect was surprising,
considering that less ethanol was used to dissolve this aliquot of vitamin D3 than the
previous batch, and that the final ethanol concentrations were only 0.01%, 0.05%, and
0.10% of the final volume for the one, five, and ten micromolar treatment stocks,
respectively.
An unexpected result was that the group of T 98 cells treated with five
micromolar vitamin D3 showed no decrease in growth compared to the control (Figure
13B). It is possible that the plate had been contaminated, although this seems unlikely
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since the luminescence values were similar to the other plates in the series. A
contaminated plate would be expected to have higher luminescence values due to the
presence of a large number of bacterial cells. An alternate explanation might have been
that the vitamin D3 was not dissolved completely, which would affect the intended
treatment concentrations. The process of vitamin D3 dilution was precarious at best—a
10 µL Hamilton syringe was used to inject only 23 µL of ethanol into the original vitamin
D3 packaging, and this volume was not fully recovered during transfer to secondary
containers. Furthermore, the dilution process was completed in the dark to prevent
vitamin D3 degradation. Even in bright conditions, the vitamin D3 used to develop
treatment stocks is sold in 0.01 mg aliquots, an amount too small to be seen. Needless to
say, it was difficult to determine whether the substance was completely dissolved.
However, it is strange that five micromolar vitamin D3 failed to inhibit growth and even
significantly increased growth in earlier assays as well (Figure 12A). Perhaps vitamin D3
may have a dose-dependent effect that stimulates proliferation at some concentrations.
This phenomenon should be further investigated in future studies.
Vitamin D3 dramatically inhibits proliferation of GBM-derived neurospheres
Although vitamin D3’s effects on differentiated GBM cell lines were inconsistent,
vitamin D3 had a much more profound inhibitory effect on BTSC proliferation, which
was expected due to BTSCs’ reliance on the hedgehog signaling pathway. Neurospheres
that had recently been differentiated by adding fetal bovine serum (FBS) in order to make
them adherent (similar to standard cell lines) showed a decrease in growth when treated
with vitamin D3 (Figure 14). Neurospheres from the same line that were left as nonadherent cultures displayed an even more robust response to vitamin D3 treatment, with
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luminescence decreasing from 100% to approximately 45% after treatment with 10 µM
vitamin D3 (Figure 15). An extended repetition of the study showed that five micromolar
vitamin D3 decreased luminescence to approximately 38% of the untreated control, while
10 µM vitamin D3 treatment decreased luminescence to approximately 6% of the
untreated control (Figure 16). Moreover, vitamin D3 was much more efficient than
cyclopamine at inhibiting neurosphere growth. Five and ten micromolar concentrations of
cyclopamine only decreased luminescence to approximately 86% and 83% of the
untreated control, respectively. Cyclopamine was slightly more effective at inhibiting the
growth of neurosphere line 259274, decreasing luminescence to 59% and 41% of vehicle
control at five and ten micromolar concentrations, respectively (Figure 17). Vitamin D3,
however, was still more effective than cyclopamine in the 259274 line, reducing
luminescence to 38% and 2% at five and ten micromolar concentrations, respectively.
These results suggest that vitamin D3 inhibits neurosphere growth in a dose-dependent
manner, and that it does so more efficiently than cyclopamine.
Differentiation should be considered as a vitamin D3-related effect
Because vitamin D3 reduced neurosphere growth more effectively than
cyclopamine, alternate vitamin D3 effects in addition to hedgehog signaling inhibition
were investigated. One hypothesis was that vitamin D3 may have been causing
differentiation of the BTSCs, which would inhibit their ability to grow and survive in the
selective neurosphere media. A simple, morphological assay was used to more closely
examine vitamin D3s effects on cellular differentiation. Results indicated that,
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Figure 14: Vitamin D3 drastically decreases newly differentiated BTSC proliferation. BTSCs
were exposed to FBS to cause differentiation for approximately two weeks before undergoing
treatment. Adherent cells were then plated at 5,000 cells per well and treated after 24 hours.
Luminescence was detected after 48 hours of treatment. Significant values indicated at p ≤ 0.05
(*), p ≤ 0.01 (**), and p ≤ 0.001 (***).
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Figure 15: Vitamin D3 drastically decreases undifferentiated BTSC proliferation.
Neurospheres were dissociated into single cell suspensions and resuspended at 50,000 cells
per milliliter in media containing respective treatments. Luminescence was detected after
48 hours of treatment. Significant values indicated at p ≤ 0.05 (***).
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Figure 16: Vitamin D3 decreases BTSC proliferation more effectively than cyclopamine in the
2503 line. Neurospheres were dissociated into single cell suspensions and resuspended at
50,000 cells per milliliter in media containing respective treatments. Luminescence was
detected after 48 hours of treatment. A star above the bar denotes a significant difference
compared to the untreated control (UT). A star above a line denotes significance of the two
indicated samples in comparison to one another. Significant values indicated at p ≤ 0.05 (*), p ≤
0.01 (**), and p ≤ 0.001 (***).
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Figure 17: Vitamin D3 decreases BTSC proliferation more effectively than cyclopamine in the
259274 line. Neurospheres were dissociated into single cell suspensions and resuspended at
50,000 cells per milliliter in media containing respective treatments. Luminescence was detected
after 48 hours of treatment. Significant values indicated at p ≤ 0.05 (*), p ≤ 0.01 (**), and p ≤
0.001 (***).
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although vitamin D3 did not cause neurosphere cells to adhere to the bottom of the flask
like FBS, it did prevent single cell suspensions from generating new spheres (Figure 18).
Too few neurospheres were generated to be able to prepare them for immunofluorescent
staining for differentiation markers, but future studies should find a way to address this
technical difficulty in order to gain a better understanding of whether vitamin D3 induces
BTSC differentiation or affects another cellular function, such as adhesion.
UT

DMSO

CYC

EtOH

Vit. D

Figure 18: Vitamin D3 prevents 2503 BTSCs from forming new neurospheres. Single cell
BTSC suspensions were treated, plated, and imaged after a four day incubation period.
Vitamin D3 prevented neurosphere formation (lower right), while the other treatments had
no observable effect.
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Vitamin D3 induces BTSC apoptosis through a caspase-dependent mechanism
Vitamin D3 has been reported in the literature to induce apoptosis at high
concentrations (Baudet et al., 1996). The luminescence-based Caspase-Glo assay
(Promega) was used to determine whether vitamin D3-related growth inhibition occurs
through an apoptotic mechanism. After eight hours of incubation, vitamin D3-treated
2503 BTSCs showed significantly increased enzymatic activity of caspases three and
seven compared to the other treatment groups (Figure 19). Cyclopamine, DMSO,
untreated cells, and ethanol-treated cells all had the same level of background
luminescence (Figure 19). There was no significant difference in caspase activity at 24
hours (data not shown).
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Figure 19: Vitamin D3 induces caspases three and seven to initiate apoptosis of BTSCs. 2503 BTSCs
were plated at 85,000 cells per well and incubated for eight hours before the addition of the CaspaseGlo® reagent (Promega). Following 30 minute incubation, luminescence was detected using a Modulus
Microplate Reader (Turner Biosystems). Significance indicated at p ≤ 0.001 (***).
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Conclusion
Clinical trials have indicated vitamin D3’s benefit to GBM patients, although its
mechanism of action has not been fully elucidated (Trouillas, et al., 2001). The
experiments detailed in this chapter demonstrated that vitamin D3 acts to inhibit GBM
cell proliferation—particularly within BTSC populations, prevent neurosphere formation,
and induce apoptosis through a caspase-dependent mechanism.
In standard GBM LN 229, T 98, U 87 MG, and U 138 MG cell lines, vitamin D3
significantly inhibited proliferation, although the effective dose varied from experiment
to experiment. The inconsistencies in vitamin D3’s effectiveness may have been caused
by the rapid degradation of active vitamin D3 within the in vitro model system chosen for
the study. In addition, the technical difficulty of diluting and storing active vitamin D3
may have contributed to its variability.
Vitamin D3’s inhibitory effects on BTSC (neurosphere) populations were much
more dramatic and consistent. Vitamin D3 inhibited neurosphere proliferation in a dosedependent manner, and addition of 10 µM vitamin D3 nearly halted proliferation in two
separate neurosphere lines. Upon morphological examination, vitamin D3 clearly
prevented neurosphere formation from a single cell suspension, although the mechanism
by which this occurred remains unclear. Future studies should consider whether
differentiation or perhaps even changes in cell-cell adhesion are caused by vitamin D3.
Interestingly, vitamin D3 was more effective than the hedgehog antagonist
cyclopamine at inhibiting BTSC proliferation (Figures 16 and 17). Previous studies have
shown that vitamin D3 more efficiently inhibits hedgehog signaling than cyclopamine
(Bijlsma, et al., 2006), which could partially explain its dramatic effects in BTSCs, which
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more strongly express the hedgehog signaling pathway than differentiated cells.
However, it is likely that vitamin D3’s other actions within the cell, such as induction of
apoptosis, contribute to its antiproliferative effects. Indeed, the data indicate that vitamin
D3 causes induction of caspase three and seven activity at a 10 µM concentration. Further
studies should consider other concentrations and cell types to more fully describe vitamin
D3’s effects.
In vitro, vitamin D3 inhibits GBM cell proliferation by antagonizing hedgehog
signaling, inducing apoptosis, preventing neurosphere formation, and potentially by
affecting other cellular mechanisms. These effects may contribute to vitamin D3’s
benefits in GBM patients, but more research needs to be done to further understand this
complex system. Overall, the findings of this study indicate the need for a closer look
into vitamin D3’s actions within GBM cells and identify vitamin D3 as a potential
adjuvant therapy for GBM treatment.
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CHAPTER 5: SUMMARY AND CONCLUSIONS

Glioblastoma multiforme (GBM) is a devastating type of brain tumor with limited
treatment options. Vitamin D3 is currently in clinical trials for GBM treatment adjuvant
to standard therapies, though its cellular effects are poorly understood. This thesis lends
support to the use of vitamin D3 as a therapeutic agent through in vitro studies of GBM
cells. Previous studies showing vitamin D3’s ability to inhibit the growth-inducing
hedgehog signaling pathway were confirmed through the observation of decreased Gli1
and MYCN expression after vitamin D3 treatment. In addition, Vitamin D3 decreased
proliferation of both standard GBM cell lines and tumor-derived neurospheres composed
of isolated BTSC populations. Interestingly, vitamin D3 inhibited BTSC proliferation
much more effectively than the standard hedgehog antagonist cyclopamine. Further
characterization studies provided evidence for vitamin D3’s ability to prevent
neurosphere formation from a single-cell suspension and induce apoptosis in BTSCs
through the activity of caspases three and seven. Future studies will further elucidate
vitamin D3’s mechanisms of action within GBM cells and determine whether these
actions are conserved in vivo.
Several limitations existed within the described experiments. For one, the
software available to analyze the immunocytochemistry results did not allow for
quantitative comparison. It appeared as though BTSCs exhibited a higher level of Gli1
compared to the standard cell lines, but further studies with more sophisticated equipment
would need to be done to accurately compare fluorescent signal between samples. It
would be interesting to use either use quantitative immunocytochemistry or quantitative
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polymerase chain reaction (qPCR) to numerically gauge differences in Gli1 expression
between bulk GBM cells and BTSCs, as well as between GBM cell lines. Such analyses
would be useful in determining whether vitamin D3’s effectiveness correlate with
hedgehog pathway expression. Furthermore, Gli1 expression could be investigated as a
potential biomarker for tumor aggression or tested for its ability to predict vitamin D3
responsiveness.
The most prominent limitation of the study was vitamin D3’s instability due to its
rapid degradation after exposure to oxygen and ultraviolet light (Lebwohl, et al., 2003).
Future studies might consider employing an in vivo model, in which a more stable, less
expensive, inactive precursor of 1-α-dihydroxyvitamin D could be substituted. 25hydroxyvitamin D3, for instance, is converted into 1α,25-dihydroxyvitamin D3 in the
mammalian liver and may be a plausible alternative to purified 1α,25-dihydroxyvitamin
D3. Active vitamin D3 may also be more stable if delivered intravenously. An in vivo
system would also allow for the delivery of vitamin D3 in an oil vehicle, which increases
its bioavailability compared to ethanol or powder. (Grossmann & Tangpricha, 2010).
These methods might circumvent some of the problems with rapid degradation that lead
to dosing inconsistencies observed in this study.
An in vivo study would also provide a more complete picture of vitamin D3s
effects on tumor biology and overall well-being. Bar and colleagues point out that GBM
tumors are multiforme, meaning that cells in different parts of the tumor may exhibit
varying levels of gene expression, including hedgehog expression (2007). In vivo studies
using an animal model would better represent human GBM tumors by exhibiting cellular
heterogeneity, which is limited in cell culture. Additionally, an in vivo model would
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allow for a better understanding of systemic effects of vitamin D3 and help find ways to
manage its limited side-effects.
Future studies might also include a broader and more complete range of doses to
pinpoint the concentration at which vitamin D3 effectively and consistently inhibits GBM
growth. It should be noted that the doses used in this study were much higher than those
that would be used in vivo, and therefore should not be considered physiologically
relevant. Others have found that certain concentrations of vitamin D3 may actually
increase proliferation in certain standard GBM cell lines (Diesel, 2005), which this study
corroborates to an extent. Once proper dosing information has been determined to
effectively inhibit cell growth, vitamin D3’s interactions with Temozolomide (TMZ), the
current standard of care for GBM patients, should also be investigated to determine
whether synergistic or inhibitory effects may occur.
Interestingly, in direct contrast to the presented experiments, previous studies
have shown that T 98 cells were resistant to vitamin D treatment and that other GBM cell
lines did not respond to vitamin D3 at 10 µM concentrations (Reichrath et al., 2010; Zou
et al., 2000). What might be controlling vitamin D3 responsiveness in GBM cells? Can
cells from the same lineage undergo changes in gene expression that affect vitamin D3
responsiveness? One suggestion from the literature is that a 220-kd protein may act as a
switch to control responsiveness to vitamin D (Zou, et al., 2000). However, the identity
or activity of this protein has not been described. Another suggestion is that the effects of
vitamin D3 treatment depend on a tumor’s P53 status (Stambolsky et al., 2010). The
question remains as to what other genes may predict vitamin D3 responsiveness and
mediate vitamin D3’s actions within the cell.
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Despite this study’s promising findings, many questions still remain. A recent
study using prostate cancer cells showed that 182 genes were upregulated and 80 were
downregulated in response to vitamin D3 treatment (Kovalenko, Zhang, Cui, Clinton, &
Fleet, 2010). Some of the effects of these genes led to suppression of Wnt, Notch, NF-κB,
and IGF1 in addition to the suppression inflammation and angiogenesis (Kovalenko, et
al., 2010). Are these same genes regulated by vitamin D3 in GBM cells, and if so, are
they regulated in the same way? An interesting aspect of this question will be to find out
whether GBM cells in culture or in patients express the vitamin D receptor (VDR), and
whether this has an effect on vitamin D3 responsiveness as suggested by other studies
(Davoust et al., 1998). If vitamin D3 is indeed able to act by inhibiting the Smo protein in
the hedgehog signaling pathway, will vitamin D3 still be able to decrease GBM
proliferation in the absence of the VDR? In the absence of the VDR, would vitamin D3’s
effects be the same as cyclopamine’s effects, or are other VDR-independent mechanisms
intact within the cells? These are all areas for further exploration.
Additionally, it is yet unclear whether vitamin D3 induces differentiation of GBM
BTSCs in the same way that it has been shown to induce differentiation and inhibit the
clonal (stem cell) population in breast cancer (Elstner et al., 1995). Eyles reviews that in
the normal neural development, vitamin D reduces proliferation and induces
differentiation and apoptosis (Eyles, et al., 2011). Do these cellular effects occur in
normal neural stem cells within the subventricular zone, and if so, will they affect the
ability for patients to regenerate parts of the brain damaged by tumor resection? These
and other questions become important when considering vitamin D3 as a GBM treatment
option.
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Vitamin D3 regulates over 200 different genes, and its deficiency is associated
with heart disease as well as 17 different types of cancer (Anaizi, 2010; Current Science,
2010). This and other studies show that much more work needs to be done to fully
understand how vitamin D3 interacts with and affects tumor growth through the
hedgehog signaling pathway as well as through other mechanisms. Basic science will
need to catch up with ongoing clinical trials to elucidate the way in which vitamin D3
interacts with bulk GBM cells and BTSCs to provide patient benefits, and how best to
capitalize on this phenomenon to develop better treatments.
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